Please note, this OEL/ADE monograph also applies to Tazemetostat hydrobromide (CAS RN 1467052-75-0) and Tazemetostat trihydrochloride (CAS RN 1403255-00-4). Tazemetostat is an orally available, small-molecule selective and S-adenosyl methionine (SAM) competitive inhibitor of histone methyltransferase enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2), with potential antineoplastic activity. It is used to treat adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. It is also indicated for adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by a Food and Drug Administration (FDA)-approved test and who have received at least 2 prior systemic therapies. It is also indicated for adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Tazemetostat, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.